ESTABLISHING A GOVERNMENT FUNDED PHARMACEUTICAL INDUSTRY IN KENYA: REDUCING MEDICINE COSTS, ENHANCING HEALTH SECURITY AND CREATING JOBS

Caroline Akoth Okuku.
Department of Accounting and Finance, Maseno University, Kenya.
Dr. Benjamin Ombok.
Department of Accounting and Finance, Maseno University, Kenya.

International Academic Journal of Economics and Finance (IAJEF) | ISSN 2518-2366

Received: 2nd July 2025

Published: 7th August 2025

Full Length Research

Available Online at: https://iajournals.org/articles/iajef_v5_i1_143_163.pdf

Citation: Okuku, C. A., Ombok, B. (2025). Establishing a government funded pharmaceutical industry in kenya: reducing medicine costs, enhancing health security and creating jobs. *International Academic Journal of Economics and Finance (IAJEF) | ISSN 2518-2366, 5*(1), 143-163.

ABSTRACT

Access to affordable, high-quality medicines remains a critical issue in Kenya's public health system. Despite a growing pharmaceutical market valued at over USD 1 billion, about 70% of medicines are imported, increasing drug prices and supply vulnerabilities. This seminar paper explores the feasibility and rationale for establishing a government-funded pharmaceutical industry in Kenya. The paper is prompted by persistent challenges in the healthcare sector, including stockpiles of expired drugs at KEMSA, fraudulent claims under the Social Health Insurance Fund (SHIF), and the suspension of donor aid by the U.S. government. The proposed industry aims to localize drug production, reduce medicine costs, improve availability, and create employment opportunities. The paper adopts a policy review and desk research approach, drawing from official reports, national strategies, and academic studies. The discussion outlines the current challenges, policy gaps, implementation strategies, and the projected socioeconomic benefits of this initiative. The findings suggest that a state-owned pharmaceutical entity, supported by public-private partnerships and strong regulatory frameworks, can significantly boost health system resilience, reduce foreign dependency, and position Kenya as a pharmaceutical leader in the region. The paper concludes with policy recommendations including investment in R&D, enforcement of local procurement policies, and institutional reforms to mitigate corruption. These interventions are essential for building a sustainable and secure pharmaceutical supply chain in Kenya.

Keywords: Pharmaceutical, Medicine, Kenya, Government, Manufacturing

INTRODUCTION

Access to affordable and high-quality medicines is critical for public health and national security. In Kenya, the pharmaceutical sector is heavily reliant on imports, which account for over 70% of the country's $1 billion drug market (IFC, 2020). This dependency contributes to inflated costs, supply disruptions, and limited access to essential drugs. Although the Kenya Medical Supplies Authority (KEMSA) oversees procurement and distribution, it does not manufacture drugs and has faced recurring governance scandals, including the expiry of medicine stocks in its warehouses (Daily Nation, 2024). These inefficiencies, coupled with declining donor support and ongoing challenges in health financing reforms such as fraudulent

claims under the Social Health Insurance Fund (SHIF) expose systemic weaknesses in the country's medical supply infrastructure.

While Kenya has implemented various policies to improve health financing, digitize procurement, and subsidize healthcare access under Universal Health Coverage (UHC), these interventions have largely failed to develop a sustainable, domestically anchored pharmaceutical manufacturing base. Existing literature and policy strategies have focused primarily on private sector regulation, import facilitation, or donor-driven procurement, with limited emphasis on public sector-led pharmaceutical production as a long-term structural solution.

Research gap

This seminar paper addresses that policy and academic gap by proposing the establishment of a government-funded pharmaceutical industry in Kenya. The central aim is to evaluate how public investment and regulatory reform can lower medicine prices, boost employment, and enhance self-sufficiency.

Research Objectives

Specifically, the study seeks to:

i. Assess the current policy and regulatory landscape;
ii. Propose a viable implementation strategy for state-led pharmaceutical manufacturing;
iii. Analyze the projected socioeconomic benefits and risks; and
iv. Determine the institutional and legal feasibility of such an initiative.

The study is grounded in the Public Goods Theory and the Industrial Policy Framework, which together justify strategic government intervention in sectors where market failures persist. The paper uses a desk-based methodology, drawing on secondary sources to synthesize data from government reports, international agencies, and academic research.

The remainder of this paper is structured as follows: Section 2 reviews the relevant literature; Section 3 outlines the methodology; Section 4 presents the findings and implementation strategy; and Section 5 concludes with policy implications.

LITERATURE REVIEW

Theoretical Framework

This seminar paper is anchored on two complementary theories: Public Goods Theory and the Industrial Policy Framework. Together, they offer a strong justification for state intervention in pharmaceutical manufacturing, especially in contexts where market forces alone cannot guarantee equitable access to essential services.

a) Public Goods Theory

This study is anchored in Public Goods Theory, which traditionally defines public goods as non-rivalrous and non-excludable resources that markets tend to underprovide (Musgrave, 1959). While most pharmaceuticals do not meet these strict criteria, essential medicines function as quasi-public goods in developing economies where equitable access is socially vital but often hindered by market forces. In Kenya, the high cost of imported drugs, persistent stockouts, and recent scandals at institutions like KEMSA reveal the inability of market-driven

systems to ensure affordable and reliable access to life-saving medicines. Such failures stem from information asymmetry between patients and providers, monopoly pricing by global pharmaceutical firms, and negative externalities resulting from untreated illnesses (Stiglitz, 1989; Arrow, 1963). These challenges justify state intervention to correct market failures and promote universal access, particularly for vulnerable populations.

However, Elinor Ostrom's critique of centralized state provision warns against overreliance on rigid bureaucracy, advocating instead for polycentric governance models that blend public oversight with private innovation (Ostrom, 1990). In this context, Public–Private Partnerships (PPPs) offer a hybrid solution where public investment in pharmaceutical manufacturing is complemented by private sector efficiency, shared research and development, and co-production of medicines. Such a strategy not only advances Universal Health Coverage (UHC) and SHIF objectives but also strengthens Kenya's health sovereignty and industrial capacity through more inclusive and sustainable governance structures.

While traditional Public Goods Theory anchored in Musgrave's (1959) conception of non-rivalry and non-excludability provides the basis for justifying government intervention, its application in the context of essential medicines in developing countries like Kenya requires a more nuanced interpretation. Medicines are best described as quasi-public goods: although not fully non-excludable or non-rival, their broad societal value and role in sustaining public health justify state action to ensure equitable access (Stiglitz, 1989). The market's inability to provide essential medicines affordably and reliably stems from specific forms of market failure, including information asymmetry (where patients lack full knowledge to assess quality or necessity), monopoly pricing (especially by multinational suppliers), and negative externalities (as untreated communicable diseases burden the wider society) (Arrow, 1963).

In light of these failures, state involvement becomes not just a moral imperative but a rational economic strategy. However, the critique by Elinor Ostrom (1990) offers a cautionary refinement: centralized, bureaucratic state provision often fails due to inefficiency, rigidity, or lack of local knowledge. Ostrom advocates for polycentric governance a framework where public agencies, private sector actors, and community stakeholders share responsibility in the production and oversight of public goods. In Kenya's case, this supports the creation of hybrid models, such as public–private partnerships (PPPs) in pharmaceutical manufacturing, which combine public investment with private innovation, improve accountability, and better reflect the complex nature of medicine access as both a social and economic good.

b) Industrial Policy Framework

This study is also grounded in the Industrial Policy Framework , which provides an economic rationale for targeted government intervention in sectors where private investment is constrained by high entry costs, long maturation periods, and uncertain returns (Rodrik, 2004). Pharmaceutical manufacturing in Kenya fits this profile it is capital-intensive, highly regulated, and essential for public health, yet remains underdeveloped. Despite its strategic importance, the industry covers only about 30% of national pharmaceutical demand and operates at under 25% of installed production capacity (Vugigi, 2017; IFC, 2020)

According to Rodrik, governments in developing countries must make "strategic bets" by investing in or de-risking critical but undercapitalized industries. In Kenya's case, pharmaceutical production suffers from coordination failures , where complementary investments in research, infrastructure, skilled labor, and procurement systems are required simultaneously. Without deliberate state support, these elements rarely align. A robust industrial policy anchored in fiscal incentives , public procurement mandates , research and development investment , and public–private partnerships (PPPs) can bridge these gaps and stimulate domestic production.

Lessons from late industrializers like India, Bangladesh, and South Korea underscore the viability of this approach. India's pharmaceutical boom followed its 1970 Patents Act, which emphasized generic production. Bangladesh leveraged its WTO TRIPS exemption to build local capacity, while South Korea's state-led industrialization succeeded through concessional finance, infant industry protection, and export incentives. Kenya can adapt not copy these models, emphasizing a hybrid strategy that combines state leadership with market responsiveness.

In this framework, a government-funded pharmaceutical firm is not merely a welfare initiative but a strategic industrial investment that promotes health security, job creation, innovation , and economic resilience. It offers a response to both market underperformance and public health imperatives , particularly in light of recent shocks such as the withdrawal of U.S. donor health funding . Ultimately, by merging the welfare focus of Public Goods Theory with the strategic logic of Industrial Policy, the case for a state-led pharmaceutical initiative in Kenya is both economically sound and socially very necessary.

Essential medicines, though not strictly public goods in the classical economic sense, function as quasi-public goods in developing economies where affordability barriers and income disparities hinder universal access (Musgrave, 1959; Stiglitz, 1989). Their societal value preventing disease spread, supporting workforce productivity, and promoting health equity warrants public intervention. Moreover, market failures such as information asymmetry between patients and providers, monopoly pricing by multinational drug suppliers, and externalities from untreated illnesses reinforce the need for state involvement (Arrow, 1963). Yet, as Elinor Ostrom (1990) cautions, centralized state control can be inefficient or overly rigid. A more effective approach lies in polycentric governance, where public–private partnerships (PPPs)balance public interest with private sector efficiency, innovation, and responsiveness.

Complementing this social rationale is the Industrial Policy Framework, which advocates for targeted state intervention in underinvested but strategic sectors. Rodrik (2004) emphasizes the importance of governments making "strategic bets" in areas where private capital is hesitant due to high fixed costs, long return horizons, or coordination failures. Pharmaceutical manufacturing in Kenya fits this profile it is capital-intensive, technologically demanding, and highly regulated. Historically, late industrializers such as India, Bangladesh, and South Korea have used similar strategies: providing infant industry protection, investing in technology

acquisition, and aligning industrial goals with export-led growth. India's 1970 Patents Act enabled a thriving generic drug industry; Bangladesh leveraged TRIPS flexibilities to expand local capacity; and South Korea built pharmaceutical and biotechnology clusters through targeted research and development support and concessional finance. Kenya can adapt this model by combining public investment, local procurement mandates, and regulatory support to build a resilient, inclusive pharmaceutical industry that delivers both health security and economic transformation.

General Economic Interventions

Kenya has implemented a range of economic policy measures aimed at stabilizing prices and enhancing social welfare. These include subsidies in food, energy, and education; technology-driven public service reforms; and price controls in utilities such as fuel and electricity (Republic of Kenya, 2019; Ministry of Energy, 2018; Ministry of Education, 2019). While such interventions have improved access to basic goods and services, their relevance to medicine affordability and pharmaceutical development remains indirect. The pharmaceutical sector continues to be characterized by high import dependency, with over 70% of medicines sourced internationally (IFC, 2020), exposing the country to supply chain disruptions and foreign exchange shocks. Moreover, although some price controls exist for essential drugs through institutions like the Pharmacy and Poisons Board (PPB) and KEMSA, enforcement is weak and fragmented (Ministry of Health, 2018). Without local manufacturing capacity, these policies cannot guarantee sustainable affordability or supply consistency. Therefore, sector-specific reforms centered on strategic pharmaceutical production, price stabilization, and technological innovation in drug formulation and distribution are needed to address the unique challenges of medicine access and health system resilience in Kenya.

Health and Pharmaceuticals Policies and Measures

a) Healthcare Subsidies and Public Financing

In the health sector, Kenya has made significant investments in reducing the cost of care through mechanisms like Universal Health Coverage (UHC), National Health Insurance Fund (NHIF) reforms, and the introduction of the Social Health Insurance Fund (SHIF). These frameworks subsidize critical services such as maternal health, cancer screening, and basic outpatient treatment (Ministry of Health, 2014; Ministry of Health, 2018). However, the impact of these subsidies is constrained by the high and often volatile cost of essential medicines, which are largely imported (IFC, 2020). Thus, a government-led pharmaceutical manufacturing initiative would be instrumental in complementing these subsidies by ensuring affordability and consistent supply of quality medicines.

b) Technological Innovations for Pharmaceutical Systems

Recent technological advancements have the potential to strengthen Kenya's pharmaceutical systems. Electronic inventory management systems at the Kenya Medical Supplies Authority (KEMSA) and county health departments are improving stock monitoring and reducing wastage. Blockchain-enabled traceability systems are being piloted to combat counterfeit medicines by authenticating the drug supply chain from production to end-user (World Bank, 2020). Additionally, integration of SHIF claim systems with hospital dispensing units enables

real-time monitoring of medicine use and helps prevent fraud (Republic of Kenya, 2023). Institutions like Kenya Medical Research Institute (KEMRI) and several private firms are investing in biotechnology, vaccine development, and formulation of generic drugs, which are critical to building a locally resilient pharmaceutical industry (Dore, 2018; Vugigi, 2017).

c) Regulatory and Supply Chain Reforms

The government has undertaken steps to improve procurement and logistics efficiency through tools like the Integrated Customs Management System (iCMS) and e-procurement platforms (Republic of Kenya, 2023). However, in the health sector, supply chain mismanagement remains prevalent. Notably, scandals such as the expiration of medicine stock at KEMSA underscore systemic weaknesses (Daily Nation, 2024). Strengthening the Pharmacy and Poisons Board (PPB) and modernizing the public distribution infrastructure are necessary steps to ensure quality assurance and accountability in the supply of essential drugs (Ministry of Health, 2018).

d) Price Controls in Healthcare

Although price controls exist in sectors like energy and education, the regulation of medicine prices remains inconsistent. While KEMSA and the PPB attempt to set price ceilings for essential medicines, weak enforcement mechanisms and dependence on private importers limit their effectiveness (IFC, 2020; Ngugi & Gitonga, 2021). A government-funded manufacturing entity would enhance the ability to stabilize prices, enforce compliance, and limit monopolistic pricing behavior.

The above policy measures, though impactful in specific areas, have not been sufficient to address the structural issues affecting pharmaceutical access and affordability in Kenya. Studies by Owuor (2018) and Dore (2018) highlight that while strategic planning and innovation are key drivers of performance, these are concentrated in the private sector with minimal government leadership. The IFC (2020) diagnostic report identifies regulatory fragmentation and a lack of strategic national coordination as major barriers to sectoral growth. Furthermore, research by Vugigi (2017) shows that only 38% of essential medicines are produced locally, with low capacity utilization and minimal R&D investment. This underperformance is compounded by recent governance failures, such as fraudulent SHIF claims and medicine stock expirations (Daily Nation, 2024). These systemic failures justify the need for a government-funded pharmaceutical enterprise an entity that can operate under principles of public health equity, cost efficiency, and industrial self-reliance.

The seminar paper, therefore, builds on the identified gaps by proposing a policy-based framework for establishing a public pharmaceutical firm. This initiative aligns with Kenya's goals under UHC, the Africa Medicines Agency (AMA), and the African Continental Free Trade Area (AfCFTA), positioning the country as both a regional health leader and a pharmaceutical manufacturing hub.

RESEARCH METHODOLOGY

This study employed a qualitative desk review methodology, relying on the systematic collection and thematic analysis of secondary data. The review focused on identifying policy

gaps, institutional weaknesses, and reform opportunities relevant to establishing a government-funded pharmaceutical industry in Kenya.

Data Sources and Selection Criteria

Sources were selected based on their relevance, credibility, and publication date (preferably post-2014). Key materials included:

i. Government policy documents (e.g., Kenya Health Policy 2014–2030, KHSSP 2018–2023, Budget Policy Statements).
ii. Regulatory and institutional reports from agencies such as the Ministry of Health, Kenya Medical Supplies Authority (KEMSA), Pharmacy and Poisons Board (PPB), and NHIF.
iii. International organization reports, including those from the World Bank, WHO, and International Finance Corporation (IFC).
iv. Academic studies and theses obtained from university repositories (e.g., University of Nairobi, Kenyatta University).
v. Peer-reviewed journals accessed through JSTOR, Scopus, and Google Scholar.
vi. Credible media investigations from Nation Media Group and VOA News that revealed systemic issues like corruption and drug expiries.

Documents were selected if they:

i. Addressed pharmaceutical manufacturing, drug pricing, health financing, or supply chain reform;
ii. Focused on Kenya or countries with comparable health sector characteristics;
iii. Had policy implications for affordability, employment, or industrial development.

Analytical Approach

The documents were analyzed using thematic content analysis. Information was coded and organized into emerging themes aligned with the paper's objectives: (i) affordability of essential medicines, (ii) local drug production, (iii) regulatory challenges, and (iv) institutional responses. Cross-validation was used where multiple sources discussed the same policy or institutional issue.

Limitations of the Study

As a desk-based study, this paper is limited by the absence of primary data, such as stakeholder interviews or field surveys, which could have provided deeper insights into implementation dynamics and institutional attitudes. Additionally, some data sources were outdated or inconsistently updated across government platforms, potentially affecting the accuracy of real-time performance indicators. While media reports offered valuable context, their use was carefully cross-checked with official records to mitigate bias.

Despite these limitations, the breadth and diversity of sources provide a robust analytical foundation for assessing the feasibility and policy logic of establishing a government-funded pharmaceutical industry in Kenya.

RESEARCH FINDINGS AND DISCUSSION

Challenges Identified

The development of Kenya's pharmaceutical and healthcare systems continues to face several persistent challenges that compromise access, affordability, and sustainability. Among these, three core issues stand out: high dependence on imports, mismanagement of medical stock and fraudulent claims, and weak enforcement of procurement and pricing regulations.

a) High Dependence on Imports

Kenya's pharmaceutical sector is heavily reliant on imports, with estimates suggesting that approximately70% of medicines and medical supplies are sourced from countries such as India, China, and Europe (IFC, 2020; Vugigi, 2017). This dependency presents several structural vulnerabilities. First, it exposes the country to foreign exchange risks and price volatility in the global market, making essential medicines unaffordable during periods of currency depreciation. Second, international supply chain disruptions such as those experienced during the COVID-19 pandemic can lead to stock-outs, delayed access, and inflated costs for both public and private health institutions.

Furthermore, reliance on imports undermines the development of domestic pharmaceutical capacity, limiting Kenya's ability to achieve health sovereignty. While local firms like Universal Corporation Ltd. and Dawa Ltd. have made strides in manufacturing generic drugs, they operate under-capacity and face significant barriers to scale due to capital constraints, limited R&D, and regulatory bottlenecks (Owuor, 2018). This situation underscores the need for a government-led intervention that not only reduces the country's import bill but also strengthens its industrial base in alignment with the African Union's Pharmaceutical Manufacturing Plan for Africa.

b) Mismanagement of Medical Stock and Fraudulent Claims

Recent revelations from the Ministry of Health highlight gross mismanagement of medical supplies and financial irregularities within Kenya's public health system. Reports indicate that large consignments of medicines expired in warehouses managed by the Kenya Medical Supplies Authority (KEMSA), representing not only a waste of public funds but also a missed opportunity to alleviate medicine shortages in public hospitals (VOA News, 2025). This problem is often attributed to poor inventory management, bureaucratic inefficiencies, and lack of accountability in the public procurement system.

Additionally, the rollout of the Social Health Insurance Fund (SHIF) has been marred by fraudulent claims from hospitals. According to recent media reports, some healthcare providers submitted exaggerated or false reimbursement claims, raising questions about the integrity of health financing mechanisms. These issues highlight the broader governance problems that plague Kenya's health sector issues that cannot be resolved solely by increasing funding but require systemic reforms in procurement, auditing, and oversight.

A government-funded pharmaceutical manufacturing firm, integrated with a robust supply and distribution network, could improve transparency and accountability. It would allow for centralized procurement, digital inventory tracking, and a tighter audit trail from production to

dispensing. This would also reduce reliance on third-party suppliers who sometimes inflate prices or collude with corrupt officials.

c) Weak Enforcement of Procurement and Pricing Regulations

Kenya has established several legal and institutional frameworks for regulating pharmaceutical procurement and pricing including the Pharmacy and Poisons Board (PPB),KEMSA, and oversight by the Public Procurement Regulatory Authority (PPRA). However, enforcement of these regulations remains weak and inconsistent. Corruption, limited technical capacity, and institutional fragmentation often lead to non-compliance with procurement laws, excessive markups on drug prices, and delays in medicine delivery.

For instance, while the Kenya Health Sector Strategic and Investment Plan (KHSSP) 2018–2023 outlines standards for medicine availability and pricing, implementation at the county and facility levels varies widely. Furthermore, the Pharmacy and Poisons Board has limited capacity to conduct regular post-market surveillance or audit private pharmacies for compliance with pricing caps on essential drugs (Ministry of Health, 2018). This leads to a situation where drug prices are unregulated in practice, especially in rural areas and informal markets, putting the burden on poor households.

By contrast, a state-owned pharmaceutical firm would allow the government to produce and distribute medicines at controlled, cost-reflective prices, bypassing inefficient procurement layers and allowing for predictable pricing structures. Moreover, integration with e-health platforms and SHIF's digital claims system could enhance transparency and reduce opportunities for manipulation.

The challenges of import dependency, mismanagement of stock and funds, and weak regulatory enforcement form a critical bottleneck to the realization of universal, affordable healthcare in Kenya. These structural and governance failures justify the establishment of a government-funded pharmaceutical industry, not only as a response to inefficiencies in the current system but also as a strategic investment in public health, national resilience, and economic development.

Proposed Implementation Strategy

To realize the vision of a sustainable, affordable, and locally driven pharmaceutical manufacturing sector in Kenya, a multi-pronged, legally sound, and institutionally coordinated strategy is essential. The following components outline how the government can intervene effectively while ensuring regulatory integrity, fiscal viability, and stakeholder engagement.

a) Policy and Regulation: Enabling Frameworks and Empowering Oversight Institutions

A foundational step is the formulation of a National Pharmaceutical Manufacturing Policy that provides a coherent legal and operational roadmap. This policy should define targets for domestic production, incentivize compliance with Good Manufacturing Practices (GMP), and align Kenya's pharmaceutical ambitions with frameworks like Vision 2030, Universal Health Coverage (UHC), and the African Medicines Agency (AMA) Treaty.

Critically, legislative action will be required to:

a. Amend procurement laws (e.g., Public Procurement and Asset Disposal Act) to allow preferential purchasing from local manufacturers.
b. Harmonize drug regulation under the Pharmacy and Poisons Act to empower the Pharmacy and Poisons Board (PPB) with enforcement capacity, post-market surveillance authority, and expedited generic drug registration (Ministry of Health, 2018).

These legal instruments will create a predictable and secure investment environment, while safeguarding medicine quality and market integrity.

b) Public Infrastructure: Revamping KEMSA and Supporting Local Manufacturers

The Kenya Medical Supplies Authority (KEMSA) must be overhauled to restore its credibility and functionality following high-profile scandals involving procurement irregularities and expired stock (Daily Nation, 2024). This revamp should involve:

i. Professionalizing leadership through merit-based recruitment.
ii. Digitizing inventory systems to enhance traceability.
iii. Decentralizing storage and dispatch centers for regional efficiency.

Simultaneously, the government should offer targeted incentives such as infrastructure grants or subsidized utilities to scale up the capacity of key domestic players like Universal Corporation Ltd., Dawa Ltd., and MEDS. These firms can serve as anchor institutions for local manufacturing expansion.

c) Financial Incentives: Tax Relief, Soft Loans, and Demand Guarantees

To overcome the high capital and operational costs in pharmaceutical production, the government should:

i. Offer tax exemptions on imported equipment, APIs (Active Pharmaceutical Ingredients), and packaging materials.
ii. Establish low-interest financing facilities through the Kenya Industrial Estates (KIE) and the Kenya Development Corporation (KDC) for R&D and SME pharmaceutical startups.

In addition, implementing a "Buy Kenyan Drugs" policy requiring public hospitals to procure a minimum percentage of essential medicines from compliant local manufacturers would stabilize demand and attract private investment.

d) Research and Development Investment: Establishing a National Drug Research Institute

Kenya's pharmaceutical sector is hindered by low R&D spending, accounting for less than 1% of staff engagement in research activities (Vugigi, 2017). To address this, the government should establish a National Drug Research Institute in partnership with KEMRI, public universities, and private sector actors.

The Institute would focus on:

i. Formulation of generic drugs.
ii. Vaccine and biotechnology innovation.
iii. Clinical trials and post-market pharmacovigilance.
iv. Domestic production of APIs.

Such an institute would align with regional regulatory frameworks such as the EAC Medicines Regulatory Harmonization (EAC-MRH) and bolster Kenya's ability to respond to public health emergencies.

e) Public–Private Partnerships (PPPs): Catalyzing Domestic and Global Collaboration

PPP models offer a dynamic vehicle for leveraging private sector expertise and public sector scale. Kenya should create an enabling PPP legal framework that supports:

i. Technology transfer agreements with WHO-prequalified global firms.
ii. Joint ventures with local companies to produce under-supplied or high-priority drugs.
iii. Collaborative R&D projects involving donors, academic institutions, and pharmaceutical start-ups.

Case studies from Bangladesh and India, where PPPs facilitated the local production of WHO-listed essential medicines, illustrate the viability of this approach (UNIDO, 2011; WHO, 2021).

f) Digital Systems: Strengthening Inventory and Supply Chain Transparency

Kenya's digital transformation presents a valuable opportunity to enhance transparency in the pharmaceutical value chain. Systems such as IFMIS, ArdhiSasa, and eCitizen show the government's growing digital capacity.

In the pharmaceutical context, digital systems can:

i. Improve inventory accuracy at KEMSA and county facilities.
ii. Enable blockchain-based traceability of medicines to curb counterfeits.
iii. Integrate SHIF claims systems with dispensing units for real-time monitoring and fraud prevention.
iv. Support data-driven forecasting for procurement and production planning.

These interventions not only enhance transparency but also reduce operational costs and improve service delivery.

g) Legal and Institutional Feasibility Considerations

Effective implementation will require:

Policy alignment with national frameworks (e.g., Kenya Vision 2030), the AMA Treaty, and regional trade policies under AfCFTA.

i. Amendments to relevant statutes, including procurement, health regulation, and industrial incentives laws.
ii. Legislative buy-in from Parliament and the Council of Governors for county-level implementation.
iii. Inter-ministerial coordination between the Ministries of Health, Trade, Industrialization, and Finance.

Without legal reform and institutional cooperation, the policy may face enforceability challenges and resistance from entrenched interests. This integrated strategy not only addresses supply-side constraints but also ensures that Kenya's pharmaceutical policy is legally viable, institutionally anchored, and regionally competitive.

Monitoring and Evaluation (M&E) Framework

A robust Monitoring and Evaluation (M&E) framework is critical to assess the effectiveness, efficiency, and impact of the proposed government-funded pharmaceutical industry. Without structured performance tracking, implementation risks such as regulatory capture, cost overruns, or unmet targets may go undetected, undermining policy credibility and outcomes.

The Ministry of Health's Pharmaceutical Services Division, in collaboration with the Kenya National Bureau of Statistics (KNBS) and the Pharmacy and Poisons Board (PPB), should take

the lead in developing a results-based monitoring and evaluation system. The framework should define clear baselines, targets, data sources, and reporting timelines.

Suggested Key Performance Indicators (KPIs): Annex 1

Dimension	Indicator	Frequency	Rationale
Access	% of essential medicines available in public facilities	Quarterly	Stock availability needs regular tracking to avoid frequent shortages
Affordability	Median price ratio (MPR) to international reference prices	Biannually	Price comparisons change moderately and require less frequent data collection
Affordability	Change in retail prices of selected essential drugs	Biannually	Reflects market trends; helps track impact of policy changes on consumer prices
Efficiency	% of stock wastage due to expiry	Quarterly	Enables timely corrective actions and inventory improvements
Governance	Number of irregular procurement incidents detected and resolved	Quarterly	Supports transparency, anti-corruption monitoring, and red-flag systems
Job Creation	Number of full-time jobs created in pharmaceutical manufacturing annually	Annually	Captures formal employment trends in a stable, cumulative format
Employment	Number of jobs created directly/indirectly in the pharmaceutical value chain	Biannually	Accounts for both formal and indirect sector employment dynamics
R&D Investment	% of pharmaceutical GDP allocated to R&D	Annually	Requires fiscal-year budget reporting and external validation
Production	% of essential medicines produced locally vs. imported	Annually	Indicates progress toward self-sufficiency; tracked via KNPA and PPB
Supply Chain	Stock-out rates of essential medicines in public hospitals	Quarterly	High-priority performance metric; enables rapid resolution
Regulatory Efficiency	Average time to register a local generic drug	Annually	Informs progress toward faster market entry for local manufacturers

Research Capacity	Number of locally developed formulations or trials initiated	Annually	Reflects long-term investment in pharmaceutical innovation
Public Procurement Compliance	Share of public facilities meeting "Buy Kenyan Drugs" policy threshold	Biannually	Tracks policy adoption at facility level; supports local production incentives
Digital System Uptake	% of KEMSA and county systems using real-time inventory platforms	Quarterly	Measures e-health infrastructure and transparency implementation

Progress reports should be submitted to the National Treasury, Parliamentary Health Committee, and made available to the public via open dashboards to ensure transparency and accountability.

A mid-term evaluation (after 3 years) and a full policy impact assessment (after 5 years) should be conducted to refine strategies, allocate budgets effectively, and address emerging gaps. Donor partners (e.g., WHO, Global Fund) and independent policy think tanks can be invited to participate in external reviews.

A well-functioning monitoring and evaluation system will not only demonstrate value for money but also build public and investor confidence in Kenya's capacity to deliver a resilient, affordable, and competitive pharmaceutical sector.

Projected Benefits

Lower Medicine Prices

One of the most significant projected benefits of a government-funded pharmaceutical industry is the reduction in the cost of essential medicines. Currently, over 70% of pharmaceuticals in Kenya are imported, subjecting prices to currency fluctuations, shipping costs, and external market shocks (IFC, 2020). By manufacturing drugs locally especially generics and high-demand essential medicines the government can bypass intermediary costs, enforce cost-based pricing models, and stabilize supply. Local production also reduces exposure to price volatility from global supply chain disruptions, such as those witnessed during the COVID-19 pandemic. Furthermore, bulk public procurement from state-owned facilities will allow for economies of scale, reducing per-unit drug costs for public hospitals and ultimately for patients (Ministry of Health, 2018). This aligns with Kenya's commitment to achieving Universal Health Coverage (UHC), where affordability remains a key access barrier.

Creation of Thousands of New Jobs

The establishment of a government-funded pharmaceutical manufacturing industry in Kenya holds substantial potential to catalyze employment across multiple sectors. Direct employment

would be generated in drug formulation, packaging, research laboratories, logistics, warehousing, and quality control, while indirect jobs would emerge in sectors such as transport, ICT, construction, raw material processing, and marketing. The pharmaceutical value chain from research to retail offers a unique opportunity to absorb both skilled and semi-skilled labor, including graduates in pharmacy, biotechnology, chemistry, and biomedical sciences.

Benchmarking international experiences underscores the job creation potential. For example, Bangladesh, through its National Drug Policy of 1982 and subsequent local production mandates, grew its pharmaceutical sector to contribute over 98% of its domestic drug needs and created more than 100,000 direct and indirect jobs within two decades (UNIDO, 2011). Similarly, India's generic pharmaceutical boom, supported by government investment and patent reforms in the early 2000s, established the country as a global supplier of affordable medicines while creating over 2.7 million jobs in manufacturing and allied industries (WHO, 2021).

In Africa, Ethiopia's public-private manufacturing clusters such as the Kilinto Industrial Park have enabled technology transfer and created over 7,000 new jobs in less than five years through targeted pharmaceutical investment (African Union Development Agency [AUDA-NEPAD], 2020). The African Medicines Agency (AMA) estimates that if African countries increased their local pharmaceutical production to meet just 50% of domestic needs, the continent could generate over 1.2 million jobs in the medium term (AMA, 2022).

In Kenya, current estimates suggest that if just 30% of imported medicines were replaced by locally manufactured equivalents, over 20,000 jobs could be created across the public and private sectors (AfDB, 2019). Beyond employment generation, this would also address Kenya's growing youth unemployment problem and support the country's broader industrialization goals under Vision 2030 and the African Continental Free Trade Area (AfCFTA) framework.

Reduced Reliance on Donors and Foreign Aid

A robust domestic pharmaceutical industry can significantly reduce Kenya's dependence on international donors and aid for health commodities. Currently, a considerable portion of Kenya's HIV, TB, and malaria medicines, as well as family planning supplies, are funded by entities such as PEPFAR, the Global Fund, and USAID (IFC, 2020). However, recent diplomatic tensions and conditional aid suspensions such as the 2024 freeze on health-related donor funds by the U.S. government highlight the vulnerabilities of donor-dependent systems. By investing in local production of antiretrovirals, vaccines, and contraceptives, Kenya can gain autonomy over its public health agenda and secure continuity of care even when donor funds are delayed or withdrawn. Additionally, a strong local industry can attract long-term concessional financing from regional institutions like the African Export-Import Bank (Afrexim bank) and the African Medicines Agency (AMA), shifting Kenya from dependency to regional leadership in health financing.

Strengthened Regional Pharmaceutical Position

Kenya is already recognized as a pharmaceutical hub in East and Central Africa, housing more than 30 registered pharmaceutical manufacturers. However, most of these firms operate below capacity due to limited support and weak policy alignment (Ngugi & Gitonga, 2021). A well-

resourced government pharmaceutical initiative, combined with industrial and trade policy support, can elevate Kenya's regional status and increase its exports of essential medicines to neighboring countries such as Uganda, Tanzania, South Sudan, and Rwanda. This supports the objectives of the African Continental Free Trade Area (AfCFTA), which encourages intra-African trade in value-added goods. Additionally, by aligning with regional standards under the East African Community Medicines Regulatory Harmonization (EAC-MRH) program, Kenya can reduce regulatory duplication, shorten approval timelines, and position itself as a preferred contract manufacturer for multinational drug companies looking to serve African markets. This regional competitiveness will contribute to increased foreign exchange earnings, improved industrial resilience, and strengthened health diplomacy across Africa.

Stakeholder Mapping and Policy Feasibility

The successful establishment of a government-funded pharmaceutical industry in Kenya depends on the collaboration and commitment of multiple stakeholders across the public, private, and development sectors. Each stakeholder plays a distinct role that can either facilitate or hinder the policy's implementation:

i. **Ministry of Health (MoH):** As the lead agency, the MoH provides overall policy leadership, oversees pharmaceutical strategy formulation, and ensures alignment with national goals such as Universal Health Coverage (UHC) and Vision 2030 (Ministry of Health, 2018).

ii. **Pharmacy and Poisons Board (PPB):** The PPB regulates drug quality, manufacturing standards, and registration. Strengthening its technical capacity and post-market surveillance functions is essential for maintaining pharmaceutical integrity (IFC, 2020).

iii. **Kenya Medical Supplies Authority (KEMSA):** Responsible for the procurement and distribution of essential medicines, KEMSA's role will be pivotal. However, recent scandals involving expired drugs and procurement irregularities underline the need for its institutional reform (Daily Nation, 2024).

iv. **Kenya Medical Research Institute (KEMRI):** KEMRI supports biotechnology, drug discovery, and vaccine R&D. It can act as a scientific hub for government-funded innovation and clinical trial oversight (KEMRI, 2023).

v. **National Health Insurance Fund (NHIF) & Social Health Insurance Fund (SHIF):** These institutions are central to health financing. Integrating their reimbursement systems with government pharmaceutical supply chains would reduce fraud and enhance efficiency (Republic of Kenya, 2023).

vi. **Private Pharmaceutical Manufacturers (e.g., Universal Corporation Ltd., MEDS):** These players are already producing generics for the local and regional market. The government can partner with them through joint ventures, technology transfer, or local raw material sourcing (Ngugi & Gitonga, 2021).

vii. **Donor Agencies (e.g., WHO, Global Fund, USAID):** Development partners provide financial and technical assistance. Their buy-in is critical, particularly as Kenya transitions from donor dependence to pharmaceutical self-sufficiency (VOA News, 2025).

viii. **Public Procurement Regulatory Authority (PPRA):** PPRA will ensure procurement transparency and compliance with public financial management laws, critical for avoiding misallocation of resources (Republic of Kenya, 2019).

Engaging these actors through inter-agency committees, public–private partnerships (PPPs), and transparent reporting frameworks will increase policy feasibility and institutional commitment.

Implementation Strategy

Legal Reform, Institutional Coordination, And Strategic Financing.

This section outlines the multi-dimensional strategy necessary for the realization of a government- funded pharmaceutical industry, with a particular focus on legal instruments, regulatory infrastructure, and blended financing models.

a) Legal Instruments: Fast-Tracking Statutory Reforms

Effective implementation will require targeted amendments to Kenya's legislative framework to align procurement, regulatory, and industrial incentives with local pharmaceutical production goals. Notably:

The Public Procurement and Asset Disposal Act should be amended to introduce a price preference mechanism, allowing public health institutions to procure medicines from local manufacturers at up to 30–40% higher cost compared to imports. This provision would create market stability and incentivize domestic production while maintaining affordability within public procurement frameworks.

The Pharmacy and Poisons Act should be revised to include expedited pathways for the registration of essential generic drugs that meet WHO prequalification or stringent GMP standards. Fast-tracked approvals will reduce time-to-market for local manufacturers while maintaining rigorous quality assurance protocols.

b) Institutional Infrastructure: Creating a Coordinating Authority

To consolidate fragmented mandates across health and industry institutions, the government should establish a Kenya National Pharmaceutical Authority (KNPA). This semi-autonomous agency would coordinate strategy, financing, and regulatory oversight across key stakeholders including the Ministry of Health, KEMSA, Treasury, PPB, and industrial development agencies.

To enhance accountability and performance, the government should implement performance-based Memoranda of Understanding (MoUs) between KNPA and critical institutions such as KEMSA, linking public financing and procurement privileges to key performance indicators (KPIs) tied to medicine availability, cost-efficiency, regulatory compliance, and wastage reduction.

c) Financial Mechanisms: De-Risking Local Investment

Pharmaceutical manufacturing is a capital-intensive and risk-prone sector, requiring blended financing mechanisms to stimulate long-term investment. The government should establish a National Medicines Investment Fund (NMIF), with pooled contributions from development partners such as the African Development Bank (AfDB), the International Finance Corporation (IFC), and the African Medicines Agency (AMA).

Priority disbursements should support:

a) Construction or upgrading of GMP-compliant production plants, especially in counties underserved by pharmaceutical services.
b) Establishment of innovation hubs within KEMRI and universities to accelerate R&D in biotechnology, vaccine development, and generic formulations.
c) Provision of working capital for SMEs involved in producing essential medicines, especially those supplying county health systems or the SHIF network.

Implementation Risks and Mitigation Measures

Despite its promise, a government-funded pharmaceutical initiative in Kenya faces several implementation risks that must be proactively addressed:

i. **Corruption and Mismanagement:** Governance lapses, especially within KEMSA, have led to procurement fraud and expired stockpiles (Daily Nation, 2024). Introducing digital procurement platforms, external audits, and independent oversight such as from the Auditor-General can increase transparency and accountability (World Bank, 2020).
ii. **Public Sector Inefficiencies:** Bureaucratic delays and poor inter-agency coordination can hamper execution. Establishing dedicated project implementation units (PIUs) with clear deliverables under the Ministry of Health would streamline activities and ensure institutional accountability (IFC, 2020).
iii. **Regulatory Delays and Fragmentation:** Delays in drug approvals due to overlapping mandates between agencies can stifle innovation. Aligning Kenya's regulatory systems with African Medicines Agency (AMA) and EAC-MRH standards can reduce duplication and speed up approvals (Rodrik, 2004).
iv. **Limited Research and Development, and Human Capacity:** Kenya's pharmaceutical sector suffers from a shortage of skilled researchers and production personnel (Vugigi, 2017). This can be mitigated by investing in local pharmaceutical training, research institutions, and global partnerships for knowledge exchange.
v. **Private Sector Crowding Out:** A large public manufacturer may disincentivize private investment. This can be avoided by defining the public firm's mandate around high-priority but low-profit medicines, while encouraging PPPs and co-financing in other areas (Ngugi & Gitonga, 2021).

Proactively managing these risks will improve institutional performance, sustain political will, and enhance public trust in the government's ability to deliver affordable, high-quality medicines.

Regulatory Reform Framework: Strengthening Pricing Oversight and Procurement Accountability

A central pillar in achieving a sustainable public pharmaceutical system is the establishment of a robust regulatory framework that addresses procurement integrity, price transparency, and anti-competitive practices. The current system suffers from irregular tendering, poor pricing discipline, and limited regulatory enforcement, which contribute to inflated medicine costs and supply chain inefficiencies.

i) Procurement Enforcement through Digital Intelligence

To eliminate corruption and inefficiencies in public drug procurement, the government should digitalize the tendering process using AI-powered fraud detection tools. These systems can

analyze bidding behavior, delivery timelines, and pricing patterns to flag anomalies such as collusion or inflated invoices across KEMSA and county procurement systems. Integration of such tools within the IFMIS platform will enhance transparency and deter tender-related malpractices.

Additionally, to resolve pricing conflicts and ensure fairness in the pharmaceutical supply chain, a Medicines Pricing Tribunal should be established under the Pharmacy and Poisons Board (PPB). This independent tribunal would adjudicate disputes between public buyers and suppliers, investigate overpricing complaints, and impose penalties on entities engaging in unethical pricing behavior.

ii) Price Control Mechanisms and Reference Pricing

To mitigate excessive pricing of essential medicines, the government should introduce a national reference pricing index modeled after WHO's Global Drug Facility and regional procurement benchmarks. This index would guide public sector procurement and serve as a baseline for private sector retail pricing. In parallel, mandatory price disclosure should be instituted for all licensed private pharmacies, and mark-up ceilings should be set such as a 30% cap on essential generic medicines to prevent excessive consumer pricing, particularly in underserved areas.

Conclusion

This seminar paper concludes that the establishment of a government-funded pharmaceutical industry is not only feasible, but strategically necessary to address Kenya's longstanding vulnerabilities in public health and pharmaceutical access. The country has made considerable strides in health financing, digital health reforms, and price regulation. However, these gains remain undermined by persistent import dependency, governance failures, fragile donor reliance, and an underdeveloped local pharmaceutical manufacturing base.

A government-backed pharmaceutical industry presents a holistic policy response: lowering drug prices, fostering employment, enhancing public sector procurement capacity, and stabilizing essential medicine supply chains. If implemented alongside strategic investments in infrastructure, R&D, regulatory strengthening, and digitized procurement systems, this initiative could position Kenya as a pharmaceutical hub under regional and continental frameworks such as the East African Community (EAC) and African Continental Free Trade Area (AfCFTA).

Nonetheless, the implementation of such an initiative is not without trade-offs. The risk of politicization and capture particularly in procurement and staffing could undermine transparency and effectiveness unless strong accountability mechanisms are enforced. Additionally, the initiative would require substantial long-term fiscal planning and alignment with broader macroeconomic policies to avoid unsustainable public expenditure. Most importantly, its success will depend on sustained consensus and cooperation among stakeholders including government agencies, private manufacturers, donors, regulators, and civil society. Without shared ownership and rigorous performance monitoring, even the best-designed policies may falter.

In summary, while the benefits are substantial, achieving them will require political will, institutional discipline, and a coherent multi-stakeholder implementation framework. Done right, this initiative can not only transform Kenya's pharmaceutical sector but also strengthen its sovereignty in health and economic development.

REFERENCES

African Development Bank. (2019). Pharmaceutical Manufacturing Plan for Africa: Business Plan for Developing Local Pharmaceutical Production. AfDB.

African Medicines Agency (AMA). (2022). Position Paper on Strengthening Africa's Pharmaceutical Sector.

Arrow, K. J. (1963). Uncertainty and the welfare economics of medical care. American Economic Review, 53(5), 941–973.

AUDA-NEPAD. (2020). Strengthening Local Pharmaceutical Production in Africa: Ethiopia Case Study. African Union Development Agency.

Daily Nation. (2025, June 30). *Health CS reveals fraudulent SHIF hospital claims under investigation*. Nation Media Group.

Dore, P. W. (2018). Innovation strategies and competitive advantage of manufacturing pharmaceutical companies in Nairobi, Kenya (Master's thesis, University of Nairobi). University of Nairobi Repository. https://erepository.uonbi.ac.ke/handle/11295/105671

Energy and Petroleum Regulatory Authority (EPRA). (2019). Energy Act No. 1 of 2019. Government of Kenya. https://www.epra.go.ke/

IFC. (2020). Kenya Pharmaceutical Industry Diagnostic Report . International Finance Corporation.

International Finance Corporation (IFC). (2020). Kenya pharmaceutical industry diagnostic report. World Bank Group.(https://www.ifc.org/en/insights-reports/2022/kenya-pharmaceutical-industry-diagnostic-report-2020)

Ministry of Education. (2019). Education Sector Report 2018/2019–2020/2021. Republic of Kenya.

Ministry of Energy. (2018). Energy and Petroleum Statistics Report 2018. Republic of Kenya.

Ministry of Health. (2018). Kenya Health Sector Strategic and Investment Plan (KHSSP) 2018–2023 .

Ministry of Health. (2018). *Kenya Health Sector Strategic Plan (KHSSP) 2018–2023*.

Musgrave, R. A. (1959). The Theory of Public Finance: A Study in Public Economy. McGraw-Hill.

Nation. (2024, December 14). *Expired drugs worth millions rot in KEMSA warehouse*. Nation Media Group.

Ngugi, J., & Gitonga, M. (2021). Generic strategies and performance of pharmaceutical manufacturing companies in Nairobi County. International Journal of Business Management, Entrepreneurship and Innovation, 3(3), 85–101.

Ostrom, E. (1990). Governing the Commons: The Evolution of Institutions for Collective Action. Cambridge University Press.

Owuor, F. O. (2018). Strategic planning and performance of pharmaceutical manufacturing firms in Kenya (Master's thesis, University of Nairobi). University of Nairobi Repository. https://erepository.uonbi.ac.ke/handle/11295/105461

Republic of Kenya. (2007). *Vision 2030*.

Republic of Kenya. (2019). Budget Policy Statement FY 2019/2020. The National Treasury and Planning.

Republic of Kenya. (2019b). Ajira Digital Program Strategic Framework. Ministry of ICT, Innovation and Youth Affairs.

Republic of Kenya. (2023). Executive Order No. 2 of 2023 on E-Government Services and Digital Transformation. Office of the President.

Rodrik, D. (2004). Industrial policy for the twenty-first century . Harvard University. https://drodrik.scholar.harvard.edu/files/dani-rodrik/files/industrial-policy-twenty-first-century.pdf

Stiglitz, J. E. (1989). Markets, Market Failures, and Development. American Economic Review, 79(2), 197–203.

Suri, T., & Jack, W. (2016). The long-run poverty and gender impacts of mobile money. Science, 354(6317), 1288–1292. https://doi.org/10.1126/science.aah5309

UNIDO. (2011). Pharmaceutical Sector Profile: Bangladesh . United Nations Industrial Development Organization.

UNIDO. (2022). *Pharmaceutical Manufacturing Plan for Africa: East Africa Report*.

United Nations Industrial Development Organization (UNIDO). (2011). Bangladesh Pharmaceutical Industry: Policy and Market Structure Report.

VOA News. (2025, March 12). *US halts health funding to Kenya over graft fears*. Voice of America.

Vugigi, E. M. (2017). Assessment of the pharmaceutical manufacturing industry in Kenya to forecast local production sufficiency (Doctoral dissertation, Kenyatta University). http://ir-library.ku.ac.ke/handle/123456789/17913

WHO. (2021). India: Pharmaceutical Country Profile . World Health Organization.

World Bank. (2020). Doing Business in Kenya 2020: Comparing Business Regulation in 47 Counties. (https://www.worldbank.org/en/country/kenya/publication/doing-business-kenya-2020)

World Health Organization (WHO). (2021). India: Pharmaceutical Country Profile. WHO.